| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Sep 26, 2016 | PRGO Perrigo Co Plc | Brown Judy L | EVP, Business Ops &CFO | Sell | 2,096 | $96.76 | $202,808.96 | -12.9% | |
| Sep 22, 2016 | AVDL Avadel Pharmaceuticals Plc | Fildes Francis | Director | Sell | 15,000 | $13.45 | $201,750.00 | -50.0% | |
| Sep 21, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 99,795 | $66.17 | $6,603,416.03 | -1.1% | |
| Sep 21, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Science Officer | Sell | 444,199 | $21.03 | $9,342,803.66 | -6.8% | |
| Sep 19, 2016 | RMTI Rockwell Medical, Inc. | Holt Kenneth L | Director | Sell | 8,075 | $6.81 | $54,977.00 | -8.3% | |
| Sep 16, 2016 | SUPN Supernus Pharmaceuticals, Inc. | Patrick Gregory S | VP, Chief Financial Officer | Sell | 2,000 | $25.00 | $50,000.00 | -35.6% | |
| Sep 15, 2016 | TLPH Talphera, Inc. | Perceptive Advisors LLC51 | 10% Owner | Sell | 392,850 | $3.70 | $1,452,811.46 | -3.4% | |
| Sep 15, 2016 | SCYX Scynexis Inc | MacHado Patrick | Director | Buy | 40,000 | $2.94 | $117,600.00 | +200.0% | |
| Sep 14, 2016 | BCRX Biocryst Pharmaceuticals Inc | Barnes Alane P70 | VP, General Counsel &Corp Sec | Sell | 8,357 | $4.27 | $35,684.39 | -9.5% | |
| Sep 9, 2016 | PRGO Perrigo Co Plc | Kunkle Gary K Jr | Director | Sell | 5,814 | $89.95 | $522,973.80 | -5.0% | |
| Sep 8, 2016 | PRGO Perrigo Co Plc | Morris Herman Jr | Director | Sell | 1,073 | $90.96 | $97,594.72 | -10.3% | |
| Sep 8, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 3,000 | $19.05 | $57,150.00 | -4.7% | |
| Sep 8, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 70,925 | $62.50 | $4,432,862.85 | -0.4% | |
| Sep 6, 2016 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 3,200 | $13.72 | $43,904.00 | -9.8% | |
| Sep 2, 2016 | AVDL Avadel Pharmaceuticals Plc | Anderson Michael S | Chief Executive Officer | Buy | 2,000 | $14.12 | $28,240.00 | +1.1% | |
| Sep 1, 2016 | AVDL Avadel Pharmaceuticals Plc | Stapleton Craig R | Director | Buy | 10,000 | $13.52 | $135,190.00 | +2.0% | |
| Sep 1, 2016 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 39,200 | $62.61 | $2,454,308.08 | -100% | |
| Sep 1, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Lee Howard | Director | Sell | 10,381 | $18.78 | $194,916.77 | -8.3% | |
| Aug 26, 2016 | AVDL Avadel Pharmaceuticals Plc | Stapleton Craig R | Director | Buy | 20,000 | $13.76 | $275,140.48 | +183.9% | |
| Aug 26, 2016 | PRGO Perrigo Co Plc | Brown Judy L | EVP, Business Ops &CFO | Sell | 2,095 | $88.28 | $184,946.60 | -11.4% | |
| Aug 25, 2016 | BCRX Biocryst Pharmaceuticals Inc | Babu Yarlagadda S66 | Senior VP - Drug Discovery | Sell | 30,000 | $4.06 | $121,800.00 | -21.2% | |
| Aug 25, 2016 | RMTI Rockwell Medical, Inc. | Holt Kenneth L | Director | Sell | 9,520 | $6.37 | $60,656.35 | -5.7% | |
| Aug 24, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 28,870 | $63.00 | $1,818,671.06 | -0.3% | |
| Aug 22, 2016 | AVDL Avadel Pharmaceuticals Plc | Anderson Michael S | Chief Executive Officer | Buy | 5,000 | $14.30 | $71,478.50 | +2.7% | |
| Aug 22, 2016 | ANIP Ani Pharmaceuticals Inc | Przybyl Arthur | President And CEO | Sell | 37,455 | $66.97 | $2,508,361.35 | -16.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.